Anti-EGFR [Matuzumab]

Absolute Antibody

Anti-EGFR [Matuzumab]

7

This antibody is derived from a mouse parental clone mAb 425 which has demonstrated anti-tumor activity against solid tumors in phase I clinical trials. The binding characterization of this antibody to human EGFR was done using ELISA. This antibody was also found to bind human EGFR with a similar avidity as the parental mouse antibody 425 (PMID: 1798701). The parental mouse antibody 425 in combination with C225 (Cetuximab) reduced growth and survival of EGFR overexpressing MDA-MB-468 breast cancer cells more effectively than either antibody alone. The combination was also reported to effectively inhibited AKT and MAPK phosphorylation in MDA-MB-468 cell (PMID: 18424917). This antibody was used in a phase 1 study to investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile in patients with solid tumors that express EGFR (PMID: 14701780). This antibody has been used in various phase I studies alone or in combination with other therapeutic agents to treat patients with various type of cancers (PMID: 16533873; 16622465; 19238629). A study reported that the antitumor effects of matuzumab and cetuximab depend on inhibition of EGFR downstream signaling mediated by Akt or Erk rather than on inhibition of EGFR itself (PMID: 18033688).

Flow Cytometry, ImmunoFluorescence, Western Blot, ELISA, Neutralisation/Blocking, Other Application

antagonist; Block; ELISA; FC; IF; WB

Research Use Only

Monoclonal

Matuzumab

EGFR

epidermal growth factor receptor

ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS, PIG61, mENA, epidermal growth factor receptor, EGFR vIII, avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, proto-oncogene c-ErbB-1, receptor tyrosine-protein kinase erbB-1

Human

IgG1

Epidermal growth factor receptor

Human

The parental mouse antibody was generated by immunizing BALB/c mice intraperitoneally with A431 cells in phosphate buffered saline (PBS). Later on the humanzied version of the antibody was created by grafting CDRs of the murine antibody onto human constant regions.

-20°C,2°C to 8°C

12352203